LAM 003

Drug Profile

LAM 003

Alternative Names: LAM-003

Latest Information Update: 19 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Undisclosed
  • Developer LAM Therapeutics; Undisclosed
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Unspecified
  • Preclinical Haematological malignancies

Most Recent Events

  • 19 Apr 2017 LAM Therapeutics completes a phase I trial in Undefined indication in USA
  • 30 Mar 2017 LAM Therapeutics plans a clinical trial for Cancer (Monotherapy, Combination) in USA
  • 30 Mar 2017 Phase-I clinical trials in Undefined indication in USA (PO) before March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top